德克萨斯治疗学院
学院
Zhiqiang an罗伯特·A·韦尔奇（Robert A. Welch）杰出大学化学主席教授兼董事
Qingyun（Jim）刘, Ph.D., Professor, Janice D. Gordon Distinguished Professor in Bowel Cancer Research
XIN（Alex）GE，博士，副教授
温莉安格·李,Ph.D., Associate Professor
Kyoji Tsuchikama,Ph.D., Associate Professor
Ningyang Zhang，博士，副教授
Clifford Stephan博士，助理教授
德克萨斯治疗学院
布朗基金会分子医学研究所（TTI-IMM）的得克萨斯州治疗学院由C. Thomas Caskey博士于2010年成立，并从得克萨斯州新兴技术基金，德克萨斯大学系统和德克萨斯大学健康科学的资金中获得了资金休斯敦中心。TTI-IMM是为治疗剂和诊断工具的发现，开发和商业化而创建的。beplay苹果手机能用吗该中心进行的研究重点是建立治疗剂的原则证明以及对药物靶标的识别和验证。
Zhiqiang博士AN，教授兼董事
An博士在制药行业中有出色的记录，包括提供几种单克隆抗体的临床候选者。他目前的主要研究兴趣是对乳腺癌抗体治beplay苹果手机能用吗疗的抗性机制。耐药性通常是现有癌症疗法临床功效的限制因素。AN博士的研究团队beplay苹果手机能用吗正在使用单克隆抗体作为平台技术研究HE/ERBB信号通路中的癌症耐药性机制。AN博士的团队正在探索癌症耐药性的机制，并发现/开发用于潜在诊断和治疗应用的抗体。An博士还是教授生物医学研究生院。
刘金博士，专业s或者
Dr. Liu’s group will be focused on understanding the functions of a group of receptors (LGR4, LGR5, and LGR6) that play critical roles in normal growth and development, as well as to the initiation, growth and metastasis of cancer, especially of colon cancer. We are in the process of identifying the endogenous ligands of these receptors. Our goal is to delineate the signaling mechanisms of these receptors and identify small molecule/biologicals that can modulate the activity of this system for the development of novel therapeutics in regenerative medicine and cancer treatment.
副教授Xin GE博士
GE博士的工作着重于生物制剂的发现和工程，例如单克隆抗体（MABS）和治疗酶。他的实验室致力于发明促进生物制剂开发的促成方法，这些方法很重要，但对于当前的技术很困难甚至不可能。绕过与大自然提供的限制，他的团队采用工程策略来简化一组体外approaches including synthetic library, rational design, functional selection, repertoire sequencing, etc. Combinations of these approaches provide a powerful means for developing highly potent mAbs of biological activities relevant to disease diagnosis and treatment. Many mAbs discovered in Dr. Ge’s lab have showed significant efficacy in various models of cancer, stroke, obesity, and neuropathic pain. In addition, mAbs originated from his group have been licensed to bio-pharm industry for further development and commercialization.
Dr. Wenliang Li, Associate Professor
Li博士的实验室有兴趣研究癌症转移的癌症转移，该转移造成了90％以上的癌症死亡。他们的大部分工作都涉及在体外和体内探索人类动物组（激酶），以鉴定癌症转移的新参与者，这是一种途径，以获取对仍然难以捉摸的转移机制的新颖见解。他们的研究的目的是发现新的预后标志物，药物靶标和更好的人类转移性疾病治疗疗法。
Dr. Kyoji Tsuchikama, Associate Professor
的主要兴趣Tsuchikama博士的实验室developing novel ADC linker technologies by taking advantage of the power of organic chemistry, medicinal chemistry, and chemical biology. One example is branched ADC linkers that can be equipped with multiple drug molecules. Most ADC linkers developed to date accommodate only single cytotoxic drugs. The clinical potential of such multiloading ADC linkers had remained unexplored because of the lack of efficient and versatile methods. The Tsuchikama lab developed efficient methods for installing dual-loading ADC linkers in a simple and quantitative manner. Based on this success, they are currently advancing the multi-loading strategy to produce next-generation ADCs for combating the cancer drug resistance and heterogeneity. These are unsolved issues in cancer chemotherapy leading to discontinuation of medication and recurrence of malignancy. They envisage that their ADC technologies will provide innovative approaches for overcoming such unsolved issues and establish a novel technology platform providing a number of valuable additions to the current list of drug candidates for the future clinical studies.
副教授Ningyan Zhang博士
蛋白酶在肿瘤微环境中包括基质金属蛋白酶（MMP）介导的蛋白水解过程在肿瘤生长，侵袭，转移和抗癌耐药性中起关键作用。张博士和她的团队将研究肿瘤微环境中蛋白酶与抗肿瘤抗体之间的相互作用，并将描绘蛋白质（MMP）在癌症对癌症抗体疗法耐药性中的作用。
Clifford Stephan博士，助理教授
Dr. Stephan received his Ph.D. from the Department of Pharmacology at Vanderbilt University, Nashville, Tennessee. He is a vascular biologist with extensive experience in pharmacology and drug discovery. Dr. Stephan began his biotechnology/pharmaceutical career at Encysive Pharmaceuticals, Houston, Texas in 1993. He started and ran the High Throughput Screening New Drug Discovery Program at Encysive, becoming its Director in 2005. Since 2007 he has served as the Director of the John S Dunn high-throughput and high-content screening core laboratory of the Gulf Coast Consortium (GCC) for Chemical Genomics and is responsible for all screening campaigns, data acquisition, analysis and database management. Beginning in 2011, Dr. Stephan will serve as the Principle Investigator for the Cancer Prevention Research in Texas (CPRIT) GCC High-Throughput Screening Program concentrating on development of drug combinations for use in cancer prevention, overcoming resistance or decreasing overall toxicity. Dr. Stephan lectures regularly on drug discovery in graduate programs and has organized GCC workshops on high–throughput screening and its application to drug discovery research.
Changes to this page must be made in writing by emailing:Bonnie.Martinez@uth.tmc.edu
